AIM:To evaluate the clinical efficacy of salvianolic acidB(SA-B)on liver fibrosis in chronic hepatitis B.METHODS:Sixty patients with definite diagnosis of liverfibrosis with hepatitis B were included in the trial.Interferon-γ(IFN-γ)was used as control drug.Thepatients took orally SA-B tablets or received muscularinjection of IFN-γ,in the double blind randomized test.The complete course lasted 6 months.The histologicalchanges of liver biopsy specimen before and after thetreatment were the main evidence in evaluation,incombination with the results of contents of serum HA,LN,Ⅳ-C,P-Ⅲ-P,liver ultrasound imaging,andsymptoms and signs.RESULTS:Reverse rate of fibrotic stage was 36.67 % inSA-B group and 30.0 % in IFN-γgroup.Inflammatoryalleviating rate was 40.0 % in SA-B group and 36.67 %in IFN-γ group.The average content of HA and IV-Cwas significantly lower than that before treatment.Theabnormal rate also decreased remarkably.Overallanalysis of 4 serological fibrotic markers showedsignificant improvement in SA-B group as comparedwith the IFN-γgroup.Score of liver ultrasound imagingwas lower in SA-B group than in IFN-γgroup(HA 36.7 %vs80 %,IV-C 3.3 % vs23.2 %).Before the treatment,ALT AST activity and total bilirubin content of patientswho had regression of fibrosis after oral administrationof SA-B,were significantly lower than those of patientswho had aggravation of fibrosis after oraladministration of SA-B.IFN-γshowed certain sideeffects(fever and transient decrease of leukocytes,occurrence rates were 50 % and 3.23 %),but SA-Bshowed no side effects.CONCLUSION:SA-B could effectively reverse liverfibrosis in chronic hepatitis B.SA-B was better than IFN-γin reduction of serum HA content,overall decrease of4 serum fibrotic markers,and decrease of ultrasoundimaging score.Liver fibrosis in chronic hepatitis B withslight liver injury was more suitable to SA-B in anti-fibrotic treatment.SA-B showed no obvious side effects. AIM: To evaluate the clinical efficacy of salvianolic acid B (SA-B) on liver fibrosis in chronic hepatitis B. METHODS: Sixty patients with definite diagnosis of liver fibrosis with hepatitis B were included in the trial.Interferon-γ (IFN-γ) was used as control drug. These patients took orally SA-B tablets or received muscular injection of IFN-γ, in the double blind randomized test. The complete course lasted 6 months. The histological changes of liver biopsy specimen before and after the treatment were the main evidence in evaluation. , incombination with the results of contents of serum HA, LN, IV-C, P-III-P, liver ultrasound imaging, and symptoms and signs.RESULTS: Reverse rate of fibrotic stage was 36.67% inSA-B group and 30.0% in IFN -γgroup.Inflammatoryalleviating rate was 40.0% in SA-B group and 36.67% in IFN-γ group.The average content of HA and IV-Cwas significantly lower than that before treatment.The normal rate of also markedly decreased. Outlineralysis of 4 serological fibrotic markers showedsi gnificant improvement in SA-B group as compared with the IFN-γ group .Score of liver ultrasound imaging was lower in SA-B group than in IFN-γgroup (HA 36.7% vs 80%, IV-C 3.3% vs23.2% treatment, ALT AST activity and total bilirubin content of patients had had regression of fibrosis after oral administration of SA-B, were significantly lower than those of patients who had aggravation of fibrosis after oraladministration of SA-B.IFN-γshowed certain side effects (fever and transient decrease of leukocytes, occurrence rates were 50% and 3.23%), but SA-Bshowed no side effects. CONCLUSION: SA-B could be able to reverse liver fibrosis in chronic hepatitis B. SA-B was better than IFN- overall decrease of4 serum fibrotic markers, and decrease of ultrasoundimaging score. Liver fibrosis in chronic hepatitis B withslight liver injury was more suitable to SA-B in anti-fibrotic treatment. SA-B showed no obvious side effects.